Pharma and Biopharma Outsourcing Solutions from Intertek - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharma and Biopharma Outsourcing Solutions from Intertek

Intertek, a leading provider of Pharmaceutical Services will highlight how its unique blend of expert pharmaceutical & biopharmaceutical analysis, auditing and regulatory services are helping to save the industry material costs whilst raising the safety of its products and reliability of its supply chains at ICSE / CPhi, Madrid, Spain, 9-11 October 2012. Stand 10E89.

In particular Intertek’s service offering for biologics will be a key focus area. With the annual sales of biologic drugs forecast to grow up to three times faster than conventional drugs over the next 5 years Intertek’s strategy has been to establish a “one stop” analytical shop specifically relating to the requirements of ICH Q6B. The team, based in UK, Ireland, Basel and Sand Diego specializes in the design and delivery of regulatory (GXP) studies relating to the physiochemical and biological activity of biomolecules, bioanalytical support and manufacturing troubleshooting.

Experts from Intertek Pharmaceutical Services will be available during ICSE to share the experience of its history of successful innovative and tailored programmes. Covering a wide scope of services for both clinical development and product testing, such as GLP bioanalysis, GMP product analysis, auditing, method development validation and remediation, GMP microbiology, manufacturing technical support or sustainability consultancy, Intertek experts will be engaging on clients’ outsourcing needs for the year ahead and beyond.

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
11%
Provide treatment for patients globally.
9%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
FindPharma Custom Search

Click here